The Jackson Laboratory (JAX), a global leader in genetics and genomic medicine, has completed its acquisition of the New York Stem Cell Foundation (NYSCF), a pioneering nonprofit dedicated to advancing cures through stem cell research.

Researchers from the Alliance for Clinical Trials in Oncology have found that two targeted immunotherapy drugs lead to high remission rates and long survival with reasonable side effects for older patients with a tough-to-treat form of leukemia. The results of Alliance A041703 Cohort 1, published in the Journal of Clinical Oncology, focused on treating patients aged 60 years and older with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) with immunotherapy medications inotuzumab ozogamicin and blinatumomab. Historically, this group has faced poor outcomes with traditional chemotherapy due to high rates of treatment-related death and relapse.

Tricking cancer cells into self-destructing could reduce risk of recurrence and death in colon cancer by 50%, says new research from UC San Diego scientists.

A new study led by researchers at Wake Forest University School of Medicine has found that a direct-to-patient digital health program can significantly increase lung cancer screening rates among people at high risk. 

Patients with muscle-invasive bladder cancer who test positive for circulating tumor (ct)DNA after surgery to remove the cancer benefit from immunotherapy with atezolizumab compared to placebo whereas ctDNA-negative patients may potentially be spared unnecessary treatment. The finding is based on results from the global, randomized, phase 3 IMvigor011 trial co-led by investigators from Dana-Farber Cancer Institute, the Technical University of Munich, and Queen Mary University of London, UK.

Results of the DYNAMIC-III trial, a multi-institutional phase II/III international study conducted at Johns Hopkins and about 20 sites in Australia and Canada, showed that by using ctDNA to guide treatment, patients who tested negative for ctDNA following surgery received less chemotherapy and had fewer hospitalizations and treatment side effects. The study was published Oct. 20 in Nature Medicine and presented at the European Society for Medical Oncology meeting in Berlin, Germany. The work was partly supported by the National Institutes of Health.

BUFFALO, NY – October 20, 2025 – A new research paper was published in Volume 16 of Oncotarget on October 16, 2025, titled “Widespread folate receptor expression in pediatric and adolescent solid tumors – opportunity for intraoperative visualization with the novel fluorescent agent pafolacianine.”